- Home
- EHGO vs IMMX Comparison
EHGO vs IMMX Comparison
Compare EHGO & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHGO
- IMMX
- Stock Information
- Founded
- EHGO 2015
- IMMX 2014
- Country
- EHGO China
- IMMX United States
- Employees
- EHGO N/A
- IMMX N/A
- Industry
- EHGO
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- EHGO
- IMMX Health Care
- Exchange
- EHGO NYSE
- IMMX Nasdaq
- Market Cap
- EHGO 47.8M
- IMMX 51.1M
- IPO Year
- EHGO 2024
- IMMX 2021
- Fundamental
- Price
- EHGO $1.98
- IMMX $1.66
- Analyst Decision
- EHGO
- IMMX Strong Buy
- Analyst Count
- EHGO 0
- IMMX 1
- Target Price
- EHGO N/A
- IMMX $7.00
- AVG Volume (30 Days)
- EHGO 8.4K
- IMMX 108.3K
- Earning Date
- EHGO 11-15-2024
- IMMX 11-11-2024
- Dividend Yield
- EHGO N/A
- IMMX N/A
- EPS Growth
- EHGO N/A
- IMMX N/A
- EPS
- EHGO 0.00
- IMMX N/A
- Revenue
- EHGO $16,963,957.00
- IMMX N/A
- Revenue This Year
- EHGO N/A
- IMMX N/A
- Revenue Next Year
- EHGO N/A
- IMMX $200.00
- P/E Ratio
- EHGO $4,999.15
- IMMX N/A
- Revenue Growth
- EHGO N/A
- IMMX N/A
- 52 Week Low
- EHGO $1.45
- IMMX $1.26
- 52 Week High
- EHGO $4.40
- IMMX $7.75
- Technical
- Relative Strength Index (RSI)
- EHGO N/A
- IMMX 45.76
- Support Level
- EHGO N/A
- IMMX $1.43
- Resistance Level
- EHGO N/A
- IMMX $1.94
- Average True Range (ATR)
- EHGO 0.00
- IMMX 0.13
- MACD
- EHGO 0.00
- IMMX -0.01
- Stochastic Oscillator
- EHGO 0.00
- IMMX 57.97
About EHGO ESHALLGO INC
Eshallgo Inc. focuses on two distinct market sectors: office supply sale and leasing, and after-sale maintenance and repair. It is an authorized distributor of brands of office equipment, including HP, Epson, Xerox, Sharp, Toshiba, Konica, Kyocera, and other brands.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.